WHO ICTRP trial
Phase I/II Clinical Study on Fully Human BCMA Chimeric Antigen Receptor…
ChiCTR2000033946 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000033946 |
|---|---|
| Public title | Phase I/II Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients with Relapsed/refractory Multiple Myeloma (FUMANBA-1) |
| Scientific title | Phase I/II Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients with Relapsed/refractory Multiple Myeloma (FUMANBA-1) |
| Primary sponsor | Huazhong University of Science Tongji Hospital, Tongji Medical College |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 1-2 |
| Countries | China |
| Conditions | Relapsed/refractory Multiple Myeloma |
| Interventions | 1×106 CAR+ cells/kg:Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection |
| Registration date | Jun 18, 2020 |
| Target size | 1×106 CAR+ cells/kg:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: